5THOMAS DA, KANTARJIAN HM, STOCK W, et al. Phase 1 muhicenter study of vincristine sulfate liposomes injec- tion and dexamethasone in adults with relapsed or refracto- ry acute lymphoblastic leukemia [ J ]. Cancer, 2009, 115 (23) : 5490 - 5498.
6CHOWDHURY S, SEROPIAN S, MARKS PW. et al. Decitabine combined with fractionated gemtuzumab ozo- gamicin therapy in patients with relapsed or refractory a- cute myeloid leukemia[ J]. Journal of Clinical Oncology, 2009,84 (9) :599 - 600.
7CHEVALLIER P, DELAUNAY J, TURLURE P, et al. Long- term disease -free survival after gemtuzumab, in- termediate -dose cytarabine, and mitoxantrone in patients with CD33 ( + ) primary resistant or relapsed acute mye- loid leukemia[ J]. Journal of Clinical Oncology, 2008, 26 (32) :5192 - 5197.
8HAROUSSEAU JL, LANCET JE, REIFFERS J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipif- arnib in patients with refractory or relapsed acute myeloid leukemia [ J ]. Blood,2007,109 (12) :5151 - 5156.
9DEANGELO DJ, YU D, JOHNSON JL, et al. Nelarabine induces complete remissions in adults with relapsed or re-fractory T - lineage acute lymphoblastic leukemia or lym- phoblastic lymphoma: Cancer and Leukemia Group B study 19801[J]. Blood, 2007, 109(12) :5136 -5142.
10TRIFILIO SM, RADEMAKER AW, NEWMAN D, et al. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction fail- ure or relapsed acute myeloid leukemia [ J ]. Leukemia Research, 2012,36(4) :394 - 396.
